|
|
|
|
| LEADER |
01013nam a22002531a 4500 |
| 003 |
AR-BaBNM |
| 005 |
20251014100446.0 |
| 007 |
ta |
| 008 |
130830s1996 fr 000 0 |||||||||spa d |
| 020 |
|
|
|a 92-832-1266-5
|
| 035 |
|
|
|a 000162418
|
| 040 |
|
|
|a AR-BaBNM
|b spa
|e aacr
|
| 080 |
|
|
|a 616-006.6
|
| 245 |
0 |
0 |
|a Some pharmaceutical drugs
|
| 260 |
|
|
|a Lyon :
|b IARC,
|c 1996.
|
| 300 |
|
|
|a 514 p.
|
| 490 |
0 |
|
|a IARC Monographs on the evaluation of the cancinogenic risk of humans ;
|v 66
|
| 500 |
|
|
|a This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Lyon, 13-20 February 1996
|
| 500 |
|
|
|a El título de la presente colección fue "IARC Monographs on the evaluation of the cancinogenic risk of chemicals to humans" hasta el No. 31
|
| 650 |
|
4 |
|a Neoplasmas
|9 6873
|
| 650 |
|
4 |
|a Productos químicos
|9 11094
|
| 710 |
1 |
|
|a World Health Organization.
|b International Agency for research on cancer
|
| 942 |
|
|
|2 udc
|c LIBRO
|n 1
|
| 999 |
|
|
|c 155270
|d 155270
|